Literature DB >> 8827179

Clinical epidemiology of amyotrophic lateral sclerosis.

B R Brooks1.   

Abstract

The introduction of palliative therapies in amyotrophic lateral sclerosis (ALS) will alter the epidemiology of ALS as it is known now. Although incidence rates will remain unchanged in the near future, prevalence rates will likely increase dramatically. Better understanding of the age-specific presentation of motor neuron diseases worldwide will shed light on the vexing questions concerning the variable incidence rates in some countries and apparent incidence gradients in North America and Europe.

Entities:  

Mesh:

Year:  1996        PMID: 8827179     DOI: 10.1016/s0733-8619(05)70264-4

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  13 in total

Review 1.  How to improve the diagnostic process.

Authors:  A Eisen
Journal:  J Neurol       Date:  1999-11       Impact factor: 4.849

Review 2.  Treatment of amyotrophic lateral sclerosis.

Authors:  A Eisen; M Weber
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 3.923

3.  Management of symptoms in amyotrophic lateral sclerosis.

Authors:  Lisa S Thibodeaux; Amparo Gutierrez
Journal:  Curr Treat Options Neurol       Date:  2008-03       Impact factor: 3.598

Review 4.  Health outcome and quality-of-life measurements in amyotrophic lateral sclerosis.

Authors:  M Swash
Journal:  J Neurol       Date:  1997-05       Impact factor: 4.849

Review 5.  Exercise and amyotrophic lateral sclerosis.

Authors:  J P Lopes de Almeida; R Silvestre; A C Pinto; M de Carvalho
Journal:  Neurol Sci       Date:  2012-01-07       Impact factor: 3.307

Review 6.  The human G93A-superoxide dismutase-1 mutation, mitochondrial glutathione and apoptotic cell death.

Authors:  H Muyderman; P G Hutson; D Matusica; M-L Rogers; R A Rush
Journal:  Neurochem Res       Date:  2009-04-28       Impact factor: 3.996

Review 7.  Prospects for the pharmacotherapy of amyotrophic lateral sclerosis : old strategies and new paradigms for the third millennium.

Authors:  Barry W Festoff; Zhiming Suo; Bruce A Citron
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 8.  Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature.

Authors:  Gary Ginsberg; Serena Lowe
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

9.  Using respiratory rate and thoracic movement to assess respiratory insufficiency in amyotrophic lateral sclerosis: a preliminary study.

Authors:  Waltteri Siirala; Tarja Saaresranta; Arno Vuori; Sanna Salanterä; Klaus T Olkkola; Riku Aantaa
Journal:  BMC Palliat Care       Date:  2012-12-27       Impact factor: 3.234

10.  Serum ferritin and metal levels as risk factors for amyotrophic lateral sclerosis.

Authors:  Muddasir Qureshi; Robert H Brown; Jack T Rogers; Merit E Cudkowicz
Journal:  Open Neurol J       Date:  2008-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.